Nexalin Tech Stock Price, News & Analysis

Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.

Nexalin Technology, Inc. (Nasdaq: NXL) is a medical device company that develops non-invasive, frequency-based neurostimulation products aimed at mental health and neurological conditions. The Nexalin news feed on Stock Titan highlights company announcements, clinical study results, regulatory milestones, and capital markets updates related to its Deep Intracranial Frequency Stimulation (DIFS™) technology.

Recent news releases describe peer-reviewed studies in Alzheimer’s disease, dementia, Attention Deficit Hyperactivity Disorder (ADHD), and a case involving gambling disorder with alcohol use disorder, where Nexalin’s 15 milliamp DIFS™ devices were associated with cognitive improvements, changes in brain network activity, and favorable safety profiles. Other updates cover regulatory approvals for the Gen-2 SYNC console in markets such as Israel, China, Brazil, and Oman, as well as U.S. FDA Q-Submission interactions for Alzheimer’s and dementia programs.

Investors and observers can use this page to follow Nexalin’s progress in advancing its Gen-2 and Gen-3 platforms, including the Gen-2 SYNC console and the Gen-3 HALO™ Clarity headset, along with developments in areas like traumatic brain injury research and international distribution agreements. News items also include information on investor events, such as webinars and conference participation, and SEC-related disclosures that may influence the company’s strategic and financial position.

By reviewing the NXL news stream, readers gain insight into how Nexalin’s DIFS™ technology is being evaluated in clinical settings, how regulators are engaging with its devices, and how the company is positioning its non-invasive, drug-free neuromodulation platform within the broader mental health and neurodegenerative disease landscape.